Moleculin Biotech, Inc. will execute a 1-for-25 reverse stock split effective December 1, 2025, reducing shares from approximately 51.6 million to 2.07 million. This decision was approved by stockholders on August 18, 2025, and aims to adjust the company's share price dynamics in the market.